Core Viewpoint - Fuhong Hanlin (02696) shares have risen over 8%, reaching a historical high of 89 HKD, with a current price of 86.2 HKD and a trading volume of 73.65 million HKD, following the announcement of the first prescription for its innovative small molecule CDK4/6 inhibitor, Fuzhoning (Citrus Acid Vemurafenib Capsules) [1] Group 1 - Fuhong Hanlin announced that Fuzhoning has received its first prescription from over ten hospitals across China, including Fudan University Shanghai Cancer Center and Chinese Academy of Medical Sciences Cancer Hospital [1] - Fuzhoning, in combination with Fulvestrant, is indicated for adult patients with hormone receptor (HR) positive and HER2 negative recurrent or metastatic breast cancer who have previously experienced disease progression after endocrine therapy [1] - The drug is owned by Jincheng Aohong Pharmaceutical, a subsidiary of Fosun Pharma, while Fuhong Hanlin is responsible for its commercialization in China [1]
港股异动 | 复宏汉霖(02696)早盘涨超8% 股价再创历史新高 复妥宁全国各地首张处方落地